Inozyme Pharma, Inc. (INZY)

Compare

0.8703

-0.0561

(-6.06%)

As of 2:14:08 PM EDT. Market Open.

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET. A live webcast of the fireside chat

GlobeNewswire 3 days ago

INZY
-6.06%
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 - - Positive interim results from ENERGY 1 trial and Expanded Access Program evaluating INZ-70

GlobeNewswire 24 days ago

INZY
-6.06%
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, from 1:10-1:40pm ET. A live webcast of the presentation can be accessed from the Inves

GlobeNewswire last month

INZY
-6.06%
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company’s Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at th

GlobeNewswire last month

INZY
-6.06%
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and stabilization or reduction in ectopic calcification and hypophosphatemia, with no radiographic evidence of rickets – - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; on track to complete dosing in January 2026, with topline data to follow in early 2026 – - Regulatory gu

GlobeNewswire 2 months ago

INZY
-6.06%
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30-2:55pm ET.

GlobeNewswire 4 months ago

INZY
-6.06%
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 4 months ago

INZY
-6.06%
Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences: The Stifel 2024 Healthcare Conference. The presentation will take place on Monday, November 18 from 3:35-4:05pm ET.The Jefferies

GlobeNewswire 4 months ago

INZY
-6.06%
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early 2026 - - Company plans to initiate registrational trials in calciphylaxis and ABCC6 Deficiency in 2025 subject to regulatory alignment and sufficient funding - - Cash, cash equivalents, and short-term investments as of September 30, 2024, expected to

GlobeNewswire 4 months ago

INZY
-6.06%
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD - - Company plans to initiate a registrational trial in calciphylaxis in 2025 subject to regulatory alignment and sufficient funding - BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme

GlobeNewswire 5 months ago

INZY
-6.06%
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company’s ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) receiving hemodialysis will be presented during a poster session at the American Society of Nephrology (AS

GlobeNewswire 5 months ago

INZY
-6.06%
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of comm

GlobeNewswire 5 months ago

INZY
-6.06%
Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

- Data underscore the urgent need for therapies that address the cardiovascular and musculoskeletal complications and long-term systemic effects of ENPP1 and ABCC6 Deficiencies in children - - Inozyme and GACI Global launched PROPEL Registry to further understanding of these rare, life-threatening diseases (NCT06302439) - BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative th

GlobeNewswire 6 months ago

INZY
-6.06%
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 from 3:45-4:20 pm ET. A live

GlobeNewswire 7 months ago

INZY
-6.06%
Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

While inflation has eased to 2.9% in July, interest rates remain elevated, with the Federal Reserve’s key rate currently at 5.25% to 5.50%. However, it is widely expected that the Fed will begin cutting rates as early as next month. A reduction in rates is likely to send ripples across various sectors, with the biotech industry being particularly affected. Biotech companies, which often operate with significant overhead costs, are especially sensitive to changes in interest rates. But with a rat

TipRanks 7 months ago

INZY
-6.06%
TNGX
Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses

Key Insights Significantly high institutional ownership implies Inozyme Pharma's stock price is sensitive to their...

Simply Wall St. 7 months ago

INZY
-6.06%
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Interim data from SEAPORT 1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 – - Cash, cash equivalents, and short-term investments as of June 30,

GlobeNewswire 7 months ago

INZY
-6.06%
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT - BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases that affect bone health and blood vessel function, today announced the publication of preclinical data supporting the p

GlobeNewswire 8 months ago

INZY
-6.06%
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 DeficiencyBOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to INZ-701 f

GlobeNewswire 8 months ago

INZY
-6.06%
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are going to take a look at where Inozyme Pharma, Inc. (NASDAQ:INZY) stands against the other biotech penny stocks. Biotech Stocks in 2024: Growth Prospects, Key Players, and Investment Opportunities In 2024, the healthcare industry has […]

Insider Monkey 8 months ago

INZY
-6.06%

Performance Overview

Return	INZY	S&P 500 (^GSPC)
YTD	-68.58%	-7.70%
1-Year	-87.86%	+4.17%
3-Year	-76.92%	+19.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Inozyme Pharma, Inc. (INZY)

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Inozyme Pharma to Present at Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Inozyme Pharma Presents New Data at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Jefferies Predicts up to 270% Rally for These 2 ‘Strong Buy’ Stocks

Institutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term losses

Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating from Analysts?

Performance Overview